Aberrant lipid metabolism has been implicated in sporadic Alzheimer’s disease (AD). The current study investigated plasma phospholipid and sphingolipid profiles in individuals carrying PSEN1 mutations responsible for autosomal dominant AD (ADAD).
Methods:
Study participants evaluated were from the Perth and Melbourne sites of the Dominantly Inherited Alzheimer Network (DIAN) study. Plasma phospholipid and sphingolipid profiles were measured using liquid chromatography coupled with mass spectrometry in 20 PSEN1 mutation carriers (MC; eight of whom were symptomatic and twelve asymptomatic, based on Clinical Dementia Rating scores) and compared with six non carriers (NC) using linear mixed models. Further, AD gold standard biomarker data obtained from the DIAN database were correlated with lipid species significantly altered between MC and NC, using Spearman’s correlation coefficient.
Results:
One-hundred and thirty-nine plasma phospholipid and sphingolipid species were measured. Significantly altered species in MC compared to NC primarily belonged to choline and ethanolamine containing phospholipid classes and ceramides. Further phosphatidylcholine species (34:6, 36:5, 40:6) correlated with cerebrospinal fluid tau (p < 0.05), and plasmalogen ethanolamine species (34:2, 36:,4) correlated with both cerebrospinal fluid tau and brain amyloid load within the MC group (p < 0.05).
Conclusion:
These findings indicate altered phospholipid and sphingolipid metabolism in ADAD and provide insight into the pathomolecular changes occurring with ADAD pathogenesis. Further, findings reported in this study allow comparison of lipid alterations in ADAD with those reported previously in sporadic AD. The findings observed in the current pilot study warrant validation in the larger DIAN cohort.
MielkeMM, LyketsosCG (2006) Lipids and the pathogenesis of Alzheimer’s disease: Is there a link?, Int Rev Psychiatry18, 173–186.
2.
NitschRM, BlusztajnJK, PittasAG, SlackBE, GrowdonJH, WurtmanRJ (1992) Evidence for a membrane defect in Alzheimer disease brain, Proc Natl Acad Sci U S A89, 1671–1675.
3.
SoderbergM, EdlundC, AlafuzoffI, KristenssonK, DallnerG (1992) Lipid composition in different regions of the brain in Alzheimer’s disease/senile dementia of Alzheimer’s type, J Neurochem59, 1646–1653.
4.
HanX, HoltzmanDM, McKeelDWJr (2001) Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry, J Neurochem77, 1168–1180.
5.
HanX, DMH, McKeelDWJr, KelleyJ, MorrisJC (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: Potential role in disease pathogenesis, J Neurochem82, 809–818.
6.
ChanRB, OliveiraTG, CortesEP, HonigLS, DuffKE, SmallSA, WenkMR, ShuiG, Di PaoloG (2012) Comparative lipidomic analysis of mouse and human brain with Alzheimer disease, J Biol Chem287, 2678–2688.
7.
WoodPL (2012) Lipidomics of Alzheimer’s disease: Current status, Alzheimers Res Ther4, 5.
8.
WhileyL, SenA, HeatonJ, ProitsiP, Garcia-GomezD, LeungR, SmithN, ThambisettyM, KloszewskaI, MecocciP, SoininenH, TsolakiM, VellasB, LovestoneS, Legido-QuigleyC, AddNeuroMedC (2014) Evidence of altered phosphatidylcholine metabolism in Alzheimer’s disease, Neurobiol Aging35, 271–278.
CuiY, LiuX, WangM, LiuL, SunX, MaL, XieW, WangC, TangS, WangD, WuQ (2014) Lysophosphatidylcholine and amide as metabolites for detecting alzheimer disease using ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabonomics, J Neuropathol Exp Neurol73, 954–963.
11.
MielkeMM, HaugheyNJ, BandaruVV, WeinbergDD, DarbyE, ZaidiN, PavlikV, DoodyRS, LyketsosCG (2011) Plasma sphingomyelins are associated with cognitive progression in Alzheimer’s disease, J Alzheimers Dis27, 259–269.
12.
MielkeMM, BandaruVV, HaugheyNJ, XiaJ, FriedLP, YasarS, AlbertM, VarmaV, HarrisG, SchneiderEB, RabinsPV, Bandeen-RocheK, LyketsosCG, CarlsonMC (2012) Serum ceramides increase the risk of Alzheimer disease: The Women’s Health and Aging Study II, Neurology79, 633–641.
13.
HardyJ (1997) Amyloid, the presenilins and Alzheimer’s disease, Trends Neurosci20, 154–159.
14.
GrimmMO, GrimmHS, PatzoldAJ, ZinserEG, HalonenR, DueringM, TschapeJA, De StrooperB, MullerU, ShenJ, HartmannT (2005) Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin, Nat Cell Biol7, 1118–1123.
15.
LandmanN, JeongSY, ShinSY, VoronovSV, SerbanG, KangMS, ParkMK, Di PaoloG, ChungS, KimTW (2006) Presenilin mutations linked to familial Alzheimer’s disease cause an imbalance in phosphatidylinositol 4,5-bisphosphate metabolism, Proc Natl Acad Sci U S A103, 19524–19529.
16.
StillwellW, WassallSR (2003) Docosahexaenoic acid: Membrane properties of a unique fatty acid, Chem Phys Lipids126, 1–27.
17.
GrimmMO, AckermannR (2005) Transurethral resection of superficial bladder cancer: Technically safe, oncologically anything but perfect, J Urol174, 2086–2087.
18.
FarooquiAA, HorrocksLA (2006) Phospholipase A2-generated lipid mediators in the brain: The good, the bad, and the ugly. Neuroscientist12, 245–260.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules, Neurology43, 2412–2414.
24.
LimWL, LamSM, ShuiG, MondalA, OngD, DuanX, CreeganR, MartinsIJ, SharmanMJ, TaddeiK, VerdileG, WenkMR, MartinsRN (2013) Effects of a high-fat, high-cholesterol diet on brain lipid profiles in apolipoprotein E epsilon3 and epsilon4 knock-in mice, Neurobiol Aging34, 2217–2224.
25.
BlighEG, DyerWJ (1959) A rapid method of total lipid extraction and purification, Can J Biochem Physiol37, 911–917.
26.
LamSM, TongL, DuanX, PetznickA, WenkMR, ShuiG (2014) Extensive characterization of human tear fluid collected using different techniques unravels the presence of novel lipid amphiphiles, J Lipid Res55, 289–298.
27.
FolsteinMF, FolsteinSE, McHughPR (1975) ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res12, 189–198.
28.
HanX, GrossRW (2005) Shotgun lipidomics: Electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples, Mass Spectrom Rev24, 367–412.
29.
KatsukiH, OkudaS (1995) Arachidonic acid as a neurotoxic and neurotrophic substance, Prog Neurobiol46, 607–636.
30.
AlmeidaT, CunhaRA, RibeiroJA (1999) Facilitation by arachidonic acid of acetylcholine release from the rat hippocampus, Brain Res826, 104–111.
31.
FontehAN, ChiangJ, CipollaM, HaleJ, DialloF, ChirinoA, ArakakiX, HarringtonMG (2013) Alterations in cerebrospinal fluid glycerophospholipids and phospholipase A2 activity in Alzheimer’s disease, J Lipid Res54, 2884–2897.
32.
GorgasK, TeiglerA, KomljenovicD, JustWW (2006) The ether lipid-deficient mouse: Tracking down plasmalogen functions, Biochim Biophys Acta1763, 1511–1526.
33.
MielkeMM, BandaruVV, HaugheyNJ, RabinsPV, LyketsosCG, CarlsonMC (2010) Serum sphingomyelins and ceramides are early predictors of memory impairment, Neurobiol Aging31, 17–24.
34.
MielkeMM, HaugheyNJ, Ratnam BandaruVV, SchechS, CarrickR, CarlsonMC, MoriS, MillerMI, CeritogluC, BrownT, AlbertM, LyketsosCG (2010) Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss, Alzheimers Dement6, 378–385.
35.
FaganAM, MintunMA, ShahAR, AldeaP, RoeCM, MachRH, MarcusD, MorrisJC, HoltzmanDM (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer’s disease, EMBO Mol Med1, 371–380.
